Weekly Program Will Highlight Best Practices for Improving Chronic Conditions Through Hemp-based CBD Products
DENVER, CO, May 03, 2018 -- Phoenix Tears, (www.phoenixtearswellness.com), a provider of Hemp-based Cannabidiol (CBD) solutions for consumers, announced it is launching a weekly syndicated radio program with the Christian Fellowship Council (CFC) to help consumers recognize and leverage the profound health benefits of Hemp-based CBD products. The program will begin May 6, 2018 with a live broadcast into some 2,500 markets around the United States. Co-hosting the program will be Janet Rosendahl-Sweeney, founder and president of Phoenix Tears, and Willie Saunders, chief executive officer of the Christian Fellowship Council.
The program will feature insights into the applications for Hemp-derived CBD products in promoting healthy lifestyles, treatment of a broad range of chronic illnesses and conditions, and non-opioid pain management. The program will also deliver updates on research initiatives, emerging regulatory matters, and information for obtaining CBD solutions. Listener ‘call-in’ segments will allow the hosts to address any questions listeners may have on CBD and Hemp-derived supplements. The live program will be recorded and replayed throughout the week on CFC radio network.
“We’re delighted to partner with the Christian Fellowship Council to unmask the profound health benefits of these products and dispel misconceptions about the medicinal effects of Hemp-based products,” explained Rosendahl-Sweeney. “As more consumers seek out alternative treatments to address their specific health conditions, we are confident that the radio program will emerge as an invaluable resource for education and serve as a portal for independent discovery and research.”
The Christian Fellowship Council radio network has an audience of over seven million people per day, and is streamed directly into 4,000 churches. According to Saunders of the Christian Fellowship Council radio network, the relationship with Phoenix Tears will extend beyond the radio broadcast, to include live events at select churches and a comprehensive online community platform where individuals can obtain the latest information on research activities and patient usage insights.
“The level of interest in CBD products continues to escalate, and we are developing plans to create a series of live church events to expand the dialogue on Hemp-based health initiatives,” said Saunders. “The combination of Janet’s expertise—and the pent-up market demand—should make our program and events extremely popular with our audience.”
Individuals interested in learning more about Phoenix Tears should visit www.phoenixtearswellness.com.
About Phoenix Tears
Phoenix Tears is a manufacturer of Hemp-based CBD products for consumer use. The company is considered one of the industry’s foremost leaders in the research, production, and use of CBD solutions.
Since its founding in 2010, the company has produced over 140 formulations, and has served nearly a quarter of one million individuals. Phoenix Tears is headquartered in Denver, Colorado, and has offices in Las Vegas and New York.
Contact: Suzanne Mattaboni Parallel Communications, Inc. [email protected] 610-261-4560


Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets
California Seeks Paramount Divestitures in Warner Bros. Merger
Ampol Profit Surges as Refining Margins Hit Record Highs
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles
Nvidia Options Price in $280 Billion Earnings Swing
Trump Buys SpaceX Shares After Record IPO
Nvidia Eyes Perplexity Investment at $30 Billion Valuation
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p
Alibaba Raises $10.2 Billion to Expand AI Infrastructure
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 



